72% of investors are considering a shift in their holdings
Leaving a legacy for the industry and beyond
Earnings per share could drop by 5%
Fund buoyed by growth in flows towards Asia
Sector leaders key to country's return to 'normality'
Opportunities in AI and disruptive tech
Four key investment areas including genomics and digitisation
No V-shaped recovery
Brexit and Covid-19 among major tailwinds for sector
Top themes for a sustainable future
Industry commentators are as split as the polls
With great power comes great responsibility. As ESG momentum intensifies, the scrutiny over the pharmaceutical sector’s role in society is increasing. How 'pharma' evolves to meet fresh ESG challenges will present challenges and opportunities for the...
Nominate now for new Rising Star Award
Look beyond quarterly figures to assess long-term value
Effective 30 June 2021
Key takeaways from Covid-19
Chinese equities have led the recovery since the March downturn, with performance supported by net flows into ETFs (along with other funds).
Manager critical of Westminster's response
W- or U-shaped recovery predicted
Abbott Laboratories among 50 holdings
Fund Manager of the Year Awards: Winner's interview with the Federated Hermes Global Emerging Markets Equity fund
Winner of the Equities: Global Emerging Markets Award
Outperformers to look out for
Top picks to weather Covid-19 storm